📊 Midday Market Take
| S&P 500 | ▲ | +0.44% |
| Nasdaq | ▲ | +0.06% |
| Dow Jones | ▲ | +1.30% |
Hey there, happy Tuesday. The major indices are all pushing higher this afternoon, with the Dow leading the charge at plus 1.30 percent while the S&P and Nasdaq hold modest gains.
The Dow's strength is being driven largely by industrial and blue-chip names catching a bid today, so keep an eye on whether that momentum holds as the final two hours of trading unfold.
Kiniksa Pharmaceuticals International, plc
|
Price
$78.89
|
Today
+24.17%
|
30 Day
+50.67%
|
90 Day
+72.82%
|
1 Year
+191.64%
|
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
3 Reasons to Watch KNSA
- Q2 Earnings Just Dropped and Shares Exploded. Kiniksa reported its second quarter 2026 financial results on July 28th, and the market responded by sending shares up more than 24% in a single session. When a stock jumps that hard on earnings day, it usually means the underlying numbers or guidance surprised investors in a meaningful way.
- This Stock Has Nearly Tripled in One Year. KNSA is up 191.64% over the past year, with momentum only accelerating as the 90-day gain sits at 72.82% and the 30-day gain at 50.67%. That kind of stacked, multi-timeframe strength is rare and signals that institutional buyers have been steadily accumulating this name, not just chasing a one-day pop.
- ARCALYST Targets a Chronic Disease With Few Competitors. Kiniksa's commercial product ARCALYST treats recurrent pericarditis, a chronic heart inflammation condition that has historically had limited treatment options available to patients. With an approved drug already on the market and a pipeline candidate in Phase 2/3 trials targeting the same condition, Kiniksa is building a focused franchise in a space it essentially owns.
He predicted the 2008 financial crisis... He predicted Trump's election in 2016... He even predicted the rise of COVID-19 writing: "The chance we don't have something on the scale of a national pandemic in the next few years is near zero" That was three months before the first reported case. If he's right again, God Bless America... Because this crisis will be tectonic in scale...and it's going to begin with the bubble popping in AI.
Click here to view his latest warningTop Market Headlines
These 2 Industrial Products Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read The Full Story3 AI stocks to buy before August 2026 (Ad)
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.
Click here to get all three AI stock names from Alexander Green
Not every market move can wait. Our text alerts deliver the ones that can't. One short alert, straight to your phone, when something is worth seeing now. No fluff. No noise. No charge.
Text Me the AlertsAre Aerospace Stocks Lagging Howmet Aerospace (HWM) This Year?
Here is how Howmet (HWM) and Moog (MOG.A) have performed compared to their sector so far this year.
Read The Full StoryWhy Investors Need to Take Advantage of These 2 Retail and Wholesale Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read The Full StoryBuy this stock tomorrow (Ad)
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.
Get this stock's ticker before it becomes a household name.3 High Yield BDC Stocks to Buy Before August
Business development companies (BDCs) remain one of the most efficient income vehicles in public markets, and August is shaping up to be a construc...
Read The Full StoryThe way you've been building your wealth is working against you (Ad)
In 2022, the last time the Fed made a major shift, the 60/40 portfolio had one of its worst years on record. Bonds collapsed, stocks fell… there was nowhere to hide. Larry Benedict saw it coming. He went 11-for-11 while most investors had no idea what hit them. He says the same pattern is setting up now — on a much bigger scale.
Click here to hear his warning and find out the one move he's making instead.📈 Also Trending
Larry Benedict generated $274 million in profits for his clients by knowing where money flows when the Federal Reserve shifts. He says Trump's Fed Takeover is triggering the most significant shift in U.S. markets in nearly 20 years. He's already identified the one ticker he expects billions to flood...
Click here to get the full details before the window closes.
If you want to make 2026 one of the most lucrative years you've ever seen, get ready for August 15. Because what's ripping toward the markets could create the biggest divide between winners and losers we've seen in years. It's all down to a huge plan coming out of Washington – one so enormous in sca...
Click here to discover it free, before the opportunity is gone.
How is Nancy Pelosi worth $413 million on a $174,000 salary? For decades, the revolving door between Washington and Wall Street kept regular folks like you locked out. Thanks to a brand-new law… (One Jeff Brown was consulted by Congressional offices on…) The "Pelosi Paradox" is coming to a swift end...
Click here to discover how you could profit from this landmark moment.